VACCINATION INFORMATION
BRUCE ROSEMAN, M.D.
ADDRESS: 140 WEST 86th St.# 1A (Columbus & Amsterdam) New York, NY 10024
OFFICE HOURS: Mon/Thu/Fri. 9:30-5:30, / / Wed. 12:00-8:00 // Tues by appointment
TELEPHONE: (212) 362-8256 FAX: (212) 724-9625 Cell phone/voice mail: 1-917-642-8990
|
|
 |
IMMUNIZATION INFORMATION
by Mandie DeVincentes RN
DTP (Diptheria-Tetanus- Pertussis) intramuscular injection. A reaction may occur within 2 hours and last up to 36 hours. If fever or irritability occur, administer Acetaminophen (Tylenol). In case of fever above 102.5 F, also provide 20-30 minute tepid/lukewarm baths and call my office.
IPV (Injected Polio Vaccine) subcutaneous injection (fatty area). Local reactions at the injection site are usually mild and transient in nature(redness and soreness at injection site). Other symptoms may occur including irritability, sleepiness, fussiness, and crying. Temperatures of over 102.5 F may occur, and if so administer Tylenol and call my office.
MMR (Measles-Mumps-Rubella) intramuscular injection. Reactions include fever and irritability to the:
MUMPS- within 24 hours
MEASLES- within one week
RUBELLA- (German Measles)- within 2 weeks, rash may appear
HIB (Haemophilus Influenzae type B) intramuscular injection. Local reactions (tenderness, swelling, and redness at injection site) are common. A low-grade fever may occur within 2 days after injection. Do not give Tylenol unless the fever rises above 101.5 F, and then call my office!
PPD (Mantoux Test for Tuberculosis exposure) is an intradermal injection on the skin surface of the forearm. It is not a vaccine. This injection determines whether you have come in contact with Tuberculosis. You must have a health care professional look at the injection site 2-3 days after receiving your shot. If you have been exposed, you will find a red reaction measuring >6mm (the size of a pencil eraser) at the injection site within 2-3 days. If you notice this, or simply are not sure, call my office.
HEPATITIS B is an intramuscular injection that is generally well tolerated. It is a series of three shots, 1st dose: at the elected date; 2nd dose: one month later; 3rd dose: 6 months after the first dose. Most commonly reported reactions are injection site soreness and fatigue, which should last no longer than 48 hours. This vaccine does not prevent hepatitis A, C, or E.
HEPATITIS A is an intramuscular injection. Adults require one shot, with a booster shot between 6 and 12 months later. Children require two shots, given one month apart (a booster shot is also recommended between 6 and 12 months after the second shot). For those of you planning on receiving this vaccine for traveling purposes, you must receive the vaccine 2 weeks prior to expected exposure.
PREVNAR (pneumococcal vaccine) intramuscular injection. This new vaccine protects infants >6 weeks old and children from seven of the most commonly detected strains of pneumococcal bacteria. It is not indicated for adults. Children in day care are at a higher risk for pneumococcal infections. The most common reactions to this shot are local tenderness and redness at the injection site. Other reactions may include fever, irritability, drowsiness, restless sleep and decreased appetite. It is a 4-shot series (the first 3 injections should be given at 2 month intervals, with a booster shot approx. 6 months after the last shot).
VARIVAX (Chicken Pox Vaccine) intramuscular injection. Children get one shot only, however adults receive two shots at eight weeks apart. Do not take any aspirin for two months after receiving the shot. You should not become pregnant for at least three months after receiving this vaccination. You cannot breast feed for two months after this shot. Possible side effects: Rash and pain at the injection site, cold symptoms, headache, fatigue, muscle pain.
TETANUS TOXOID is an intramuscular injection intended for those over 7 years old. Local reactions may include redness and tenderness at the injection site. Other reactions may include fever, rash, malaise and nausea. These reactions will occur 2 to 8 hours after the injection. A booster shot is recommended every 7 to 10 years. Adverse reactions may be more severe in persons who have received multiple boosters, and if you are concerned
please call my office!
MENOMUNE (meningococcal polysaccharide vaccine) is an intramuscular injecton intended to prevent and control certain outbreaks of meningococcal disease. It is not given to children under 2 years old. This vaccine is recommended every 3 years. Adverse reactions are mild and consist of pain and redness at the injection site for 1 to 2 days. A low-grade fever may develop in children. All reactions should resolve in 48 hours. If you still have a reaction after this amount of time, call my office!
PEDIARIX is a vaccine that can protect your child against 5 serious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and polio, with just 3 doses of 1 vaccine. Vaccinating with PEDIARIX reduces the number of shots your child needs to receive by as many as 6. This may mean less pain and discomfort for your child and less stress for you. PEDIARIX provides the same proven level of protection that children have received for many years, now with up to 6 fewer shots during your baby's first year! PEDIARIX is safe and effective, and from a leader in childhood vaccines. to see an immunization schedule with PEDIARIX click here
AMERICAN ACADEMY OF FAMILY PHYSICIANS IMMUNIZATION SCHEDULE
Recommended Childhood Immunization Schedule
This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2002, for children through age 18 years. Any dose not given at the recommended age should be given at any subsequent visit when indicated and feasible. Indicates age groups that warrant special effort to administer those vaccines not previously given. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and the vaccine's other components are not contraindicated. Providers should consult the manufacturers' package inserts for detailed recommendations.
|
Hepatitis B vaccine (HepB). All infants should receive the first dose of hepatitis B vaccine soon after birth and before hospital discharge; the first dose may also be given by age 2 months if the infant’s mother is HBsAg-negative. Only monovalent HepB can be used for the birth dose. Monovalent or combination vaccine containing HepB may be used to complete the series. Four doses of vaccine may be administered when a birth dose is given. The second dose should be given at least 4 weeks after the first dose, except for combination vaccines which cannot be administered before age 6 weeks. The third dose should be given at least 16 weeks after the first dose and at least 8 weeks after the second dose. The last dose in the vaccination series (third or fourth dose) should not be administered before age 6 months.
Infants born to HBsAg-positive mothers should receive HepB and 0.5 mL Hepatitis B Immune Globulin (HBIG) within 12 hours of birth at separate sites. The second dose is recommended at age 1-2 months. The last dose in the vaccination series should not be administered before age 6 months. These infants should be tested for HBsAg and anti-HBs at 9-15 months of age.
Infants born to mothers whose HBsAg status is unknown should receive the first dose of the HepB series within 12 hours of birth. Maternal blood should be drawn as soon as possible to determine the mother's HBsAg status; if the HBsAg test is positive, the infant should receive HBIG as soon as possible (no later than age 1 week). The second dose is recommended at age 1-2 months. The last dose in the vaccination series should not be administered before age 6 months.
Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose and the child is unlikely to return at age 15-18 months. Tetanus and diphtheria toxoids (Td) is recommended at age 11-12 years if at least 5 years have elapsed since the last dose of tetanus and diphtheria toxoid-containing vaccine. Subsequent routine Td boosters are recommended every 10 years.
Haemophilus influenzae type b (Hib) conjugate vaccine. Three Hib conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required. DTaP/Hib combination products should not be used for primary immunization in infants at ages 2, 4 or 6 months, but can be used as boosters following any Hib vaccine.
Measles, mumps, and rubella vaccine (MMR). The second dose of MMR is recommended routinely at age 4-6 years but may be administered during any visit, provided at least 4 weeks have elapsed since the first dose and that both doses are administered beginning at or after age 12 months. Those who have not previously received the second dose should complete the schedule by the 11-12 year old visit.
Varicella vaccine. Varicella vaccine is recommended at any visit at or after age 12 months for susceptible children, i.e. those who lack a reliable history of chickenpox. Susceptible persons aged >=13 years should receive two doses, given at least 4 weeks apart.
Pneumococcal vaccine. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children age 2-23 months. It is also recommended for certain children age 24-59 months. Pneumococcal polysaccharide vaccine (PPV) is recommended in addition to PCV for certain high-risk groups. See MMWR 2000;49(RR-9);1-38.
Hepatitis A vaccine. Hepatitis A vaccine is recommended for children and adolescents in selected states and regions, and for certain high-risk groups; consult your local public health authority. Children and adolescents in these states, regions, and high risk groups who have not been immunized against hepatitis A can begin the hepatitis A vaccination series during any visit. The two doses in the series should be administered at least 6 months apart. See MMWR 1999;48(RR-12);1-37.
Influenza vaccine. Influenza vaccine is recommended annually for children age >=6 months with certain risk factors (including but not limited to asthma, cardiac disease, sickle cell disease, HIV, diabetes, and household members of persons in groups at high risk; see MMWR 2002;51(RR-3);1-31), and can be administered to all others wishing to obtain immunity. In addition, healthy children age 6-23 months are encouraged to receive influenza vaccine if feasible because children in this age group are at substantially increased risk for influenza-related hospitalizations. Children aged <=12 years should receive vaccine in a dosage appropriate for their age (0.25 mL if age 6-35 months or 0.5 mL if aged >=3 years). Children aged <=8 years who are receiving influenza vaccine for the first time should receive two doses separated by at least 4 weeks.
